Expertise
- Antibody
- Biotechnology
- Pharma
- Gene therapy
- Medical Technology
- Oligonucleotide
- Medicines
I completed my PhD as a neurobiologist and obtained a double degree from Maastricht University (NL) and the University of Birmingham (UK). My research focused on the molecular interaction between different brain cell types in relation to vascular dementia. I conducted fundamental research in both in vitro and in vivo models. I also investigated the potential of modulating small molecules as a possible therapeutic strategy and identified novel biomarkers for the early diagnosis of vascular dysfunction in the brain.
I believe that conducting fundamental research is essential for innovation and drives the development of novel therapies. In doing so, I strive to protect the rights and intellectual properties of the innovators that shape these inventions. My expertise will enable me to have an in-depth understanding of the technical background and importance of clients’ inventions, focusing on protecting the client’s needs and rights.
Training & Education
- PhD Neuroscience and cardiovascular research, Maastricht University (NL) and University of Birmingham (UK) [2024]
- MSc Cognitive and Clinical Neuroscience, Maastricht University [2018]
- BSc Biomedical Sciences, Maastricht University [2016]
Publications
- Wnt7a Decreases Brain Endothelial Barrier Function Via β-Catenin Activation. Mol Neurobiol. 2023 Dec 26. doi: 10.1007/s12035-023-03872-0. Epub ahead of print. PMID: 38147228.
- Hypoxic oligodendrocyte precursor cell-derived VEGFA is associated with blood-brain barrier impairment. Acta Neuropathol Commun. 2023 Aug 7;11(1):128. doi: 10.1186/s40478-023-01627-5. PMID: 37550790; PMCID: PMC10405482.
- A Systematic Review of WNT Signaling in Endothelial Cell Oligodendrocyte Interactions: Potential Relevance to Cerebral Small Vessel Disease. Cells. 2020 Jun 25;9(6):1545. doi: 10.3390/cells9061545. PMID: 32630426; PMCID: PMC7349551.